Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.

Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. · 2022

Read Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. by Wolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS. (2022) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8718224.txt.

Introduction

Wolchok and co-authors report 6.5-year outcomes from a trial of immune drugs in advanced melanoma. Patients with untreated, inoperable disease were split into three groups. One got nivolumab plus ipilimumab, one got nivolumab alone, and one got ipilimumab alone. Group sizes were near equal, at just over 300 each.

Median survival was 72.1 months in the combo group. It was 36.9 months with nivolumab and 19.9 months with ipilimumab. Survival rates at 6.5 years also favored the combo. Gains held in tumors with and without the BRAF mutation. The authors frame the combo as a durable gain for this cancer.

Catalog record

CREATORWolchok JD, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Butler MO, Hill A, Márquez-Rodas I, Haanen JBAG, Guidoboni M, Maio M, Schöffski P, Carlino MS, Lebbé C, McArthur G, Ascierto PA, Daniels GA, Long GV, Bas T, Ritchings C, Larkin J, Hodi FS.
YEAR2022
COLLECTIONPAPERS
FORMATTXT
FILE SIZE57 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8718224

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma By Jedd D Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D Lao, C Lance Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie Published in: Journal of Clinical Oncology DOI: 10.1200/JCO.21.02229 ABSTRACT Abstract PURPOSE In the phase III CheckMate 067 trial, durable clinical benefit was demonstrated previously with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab. Here, we report 6.5-year efficacy and safety outcomes. PATIENTS AND METHODS Patients with previously untreated unresectable stage III or stage IV melanoma were randomly assigned 1:1:1 to receive nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks (four doses) followed by nivolumab 3 mg/kg once every 2 weeks (n = 314), nivolumab 3 mg/kg once every 2 weeks (n = 316), or ipilimumab 3 mg/kg once every 3 weeks (four doses; n = 315). Coprimary end points were progression-free survival and overall survival (OS) with nivolumab plus ipilimumab or nivolumab versus ipilimumab. Secondary end points included objective response rate, descriptive efficacy assessments of nivolumab plus ipilimumab versus nivolumab alone, and safety. Melanoma-specific survival (MSS; descriptive analysis), which excludes deaths unrelated to melanoma, was also evaluated. RESULTS Median OS (minimum follow-up, 6.5 years) was 72.1, 36.9, and 19.9 months in the combination, nivolumab, and ipilimumab groups, respectively. Median MSS was not reached, 58.7, and 21.9 months, respectively; 6.5-year OS rates were 57%, 43%, and 25% in patients with BRAF-mutant tumors and 46%, 42%, and 22% in those with BRAF–wild-type tumors, respectively. In patients who discontinued treatment, the median treatment-free interval was 27.6, 2.3, and 1.9 months, respectively. Since the 5-year analysis, no new safety signals were observed. CONCLUSION These 6.5-year CheckMate 067 results, which include the longest median OS in a phase III melanoma trial reported to date and the first report of MSS, showed durable, improved clinical outcomes with nivolumab plus ipilimumab or nivolumab versus ipilimumab in patients with advanced melanoma and, in descriptive analyses, with the combination over nivolumab monotherapy. INTRODUCTION The development of immune checkpoint inhibitors and BRAF- and MEK-targeted therapies has led to a transformation of survival outcomes in patients with advanced melanoma.1 In particular, the programmed cell death 1 inhibitors nivolumab and pembrolizumab and the cytotoxic T-lymphocyte–associated protein-4 blocking antibody ipilimumab have reshaped immunologic approaches to the treatment of this disease. Evidence from the randomized controlled, double-blind phase II CheckMate 069 and phase III CheckMate 067 trials established the combination of nivolumab and ipilimumab as a standard care option for patients with metastatic melanoma.2-7 CONTEXT Key Objective Long-term survival of patients with advanced melanoma treated with nivolumab plus ipilimumab and nivolumab alone versus ipilimumab has been demonstrated after 5-year follow-up in the phase III CheckMate 067 trial. The extent of the durability of this benefit is of interest. We present 6.5-year results from CheckMate 067, including a first report of melanoma-specific survival. Knowledge Generated Prolonged survival can be attained in patients with melanoma treated with nivolumab plus ipilimumab or nivolumab alone with median overall survival of 72.1 and 36.9 months, and median melanoma-specific survival not reached and 58.7 months, respectively. The majority of these patients are off treatment and have not yet started systemic subsequent therapy. Relevance These results represent a substantial development in the melanoma treatment landscape versus the standard median survival of 8 months a decade ago. This advance is supported by the ability to distinguish melanoma-specific from overall survival. A 5-year follow-up analysis of the CheckMate 067 trial demonstrated durable clinical benefit with nivolumab plus ipilimumab or nivolumab alone compared with ipilimumab monotherapy.7 At 5 years, median overall survival (OS) was not reached in patients in the combination therapy group and was 36.9 and 19.9 months in the nivolumab and ipilimumab monotherapy groups, respectively. Five-year OS rates were 52%, 44%, and 26% in the three groups, respectively, and among patients with BRAF-mutant advanced melanoma, 5-year OS rates were 60%, 46%, and 30%, respectively. Noting that the study was not designed to compare the nivolumab-containing treatment groups, these results also suggested improved clinical outcomes with combination therapy over nivolumab monotherapy. Compared with either monotherapy group, treatment with the combination also resulted in higher proportions of patients who were alive and treatment-free at 5 years. Little is known about the long-term outcomes of nivolumab plus ipilimumab or nivolumab alone in melanoma beyond 5 years. In the current report, we describe an analysis of efficacy and safety in CheckMate 067 at 6.5 years of follow-up, which is the longest follow-up of a phase III trial with an anti-programmed cell death 1–based treatment in melanoma. In addition to reporting updates on long-term survival and safety, our analysis included melanoma-specific survival (MSS), which is increasingly valuable in removing the non–disease-related deaths that become an increasingly important consideration with long-term follow-up. PATIENTS AND METHODS Patients Eligible adult patients had previously untreated and unresectable or metastatic histologically confirmed stage III or stage IV melanoma with known BRAF V600 mutation status and an Eastern Cooperative Oncology Group performance status of 0 or 1. Trial eligibility criteria have been described in detail previously.4-6 All patients provided written informed consent. Study Design, Treatment, and Assessments The design of this trial and the assessments used have been detailed previously.4-6 In brief, patients were randomly assigned (1:1:1) to receive nivolumab 1 mg/kg plus ipilimumab 3 mg/kg once every 3 weeks for four doses, followed by nivolumab 3 mg/kg once every 2 weeks; nivolumab 3 mg/kg once every 2 weeks; or ipilimumab 3 mg/kg once every 3 weeks for four doses. All treatment regimens were appropriately placebo-matched for the purposes of blinding. Stratification factors were BRAF mutation status, American Joint Committee on Cancer (seventh edition) metastasis stage, and tumor programmed cell death ligand 1 status. Treatment was discontinued in the event of progressive disease (PD), the occurrence of unacceptable toxic events, or withdrawal of consent. Treatment could be continued beyond PD on the basis of clinical benefit without substantial adverse events (AEs) per investigator decision. Progression-free survival (PFS; investigator-assessed) and OS in the combination or the nivolumab group compared with the ipilimumab group were coprimary end points. Secondary end points included comparison of investigator-assessed objective response rates (ORRs) in the nivolumab-containing groups and the ipilimumab group, comparison of efficacy in the combination and the nivolumab groups (descriptive analyses), and safety. MSS (which excludes deaths unrelated to melanoma) and survival outcomes by best overall response were descriptive post hoc analyses. AEs were defined using the Medical Dictionary for Regulatory Activities version 23.0 and graded on the basis of Common Terminology Criteria for Adverse Events version 4.0. Immune-mediated AEs, defined as events for which immune-modulating medication was initiated (except for endocrine events, which did not require immune-modulating medication initiation to be included), and select AEs (defined as events with a potential immunologic cause in the categories of skin, gastrointestinal, hepatic, pulmonary, renal, hypersensitivity or infusion reaction, or endocrine) were evaluated. Additional exploratory analyses (survival outcomes in other subgroups, treatment-free interval [TFI; the time from the last dose of study drug to subsequent systemic therapy initiation or the last known date alive, excluding patients who had discontinued study follow-up or had died before receiving subsequent systemic therapy], and treatment-free

Read the complete text